北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 2023 年第二次临时股东大会的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650034 北京德恒（昆明）律师事务所（下称"本所"）作为贵公司的常年法律顾问， 本次指派谢峰律师、毛盈四律师出席贵公司 2023 年第二次临时股东大会（以下 简称"本次股东大会"），并按照律师行业公认的业务标准、道德规范及勤勉尽 责精神，对贵公司提供的与本次股东大会有关的文件资料进行了审查，现根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》及 贵公司《章程》的规定，就贵公司本次股东大会的相关问题出具如下法律意见： 一、关于本次股东大会的召集和召开程序 根据贵公司提供的有关资料及公开披露的信息，表明贵公司已于2023年7月 25日召开了董事会会议，作出了关于召开本次股东大会的决议，并于2023年7月 26日在《中国证券报》《上海证券报》《证券时报》《证券 ...

健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司 会议资料 股票代码：605266 股票简称：健之佳 中国 昆明 二〇二三年八月 1 JZJ Chain Drugstore Corporation 2023 年第二次临时股东大会 健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司 2023 年第二次临时股东大会会议资料目录 | 会议须知 3 | | | --- | --- | | 会议议程 5 | | | 关于调整 | 2021 年限制性股票激励计划首次授予部分回购数量及回购价格并回 | | 购注销部分限制性股票的议案 7 | | | 关于公司修订《公司章程》的议案 12 | | 2 健之佳医药连锁集团股份有限公司 2023 年第二次临时股东大会 会议须知 一、股东参加股东大会，应当认真履行其法定义务，不得侵犯其他股东权益。 二、出席会议的股东（或股东代理人）须在会议召开前 15 分钟到达会议现 场办理签到手续，并请按规定出示本人身份证或其他能够表明其身份的有效证件 或证明、股东账户卡、加盖法人公章的企业法人营业执照复印件（法人股东）、 授权委托书（股东代理人）、持股凭证等文件，经验 ...

证券代码：605266 证券简称：健之佳 公告编号：2023-056 健之佳医药连锁集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次被担保方河北唐人医药有限责任公司（以下简称"唐人医药"）为健 之佳医药连锁集团股份有限公司（以下简称"公司"）的控股子公司，公司持有 其 80%股权，为公司关联方。 本次唐人医药全体股东为其提供的担保总金额为 5,000 万元，各方股东 按照持股比例确定担保额度。根据公司持股比例，公司为唐人医药提供担保 4,000 万元，其余股东合计提供担保 1,000 万元。截至本公告披露日，公司为唐 人医药已实际提供的担保余额为 0 万元。 一、担保情况概述 （一）担保基本情况简介 近期，唐人医药与招商银行股份有限公司唐山分行（以下简称"招商银行"） 签署《授信协议》，在 2023 年 8 月 8 日至 2024 年 8 月 7 日的授信期间，招商银 行向唐人医药提供总额人民币 5,000 万元的授信额度，授信业务品种为贷款、商 业承兑 ...

证券代码：605266 证券简称：健之佳 公告编号：2023-057 健之佳医药连锁集团股份有限公司 关于注销首次公开发行股票募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、首次公开发行募集资金基本情况 健之佳医药连锁集团股份有限公司（以下简称"公司"）首次公开发行股票 的申请，经中国证券监督管理委员会"证监许可[2020]2624 号"文《关于核准 云南健之佳健康连锁店股份有限公司首次公开发行股票的批复》核准，公司向社 会公开发行人民币普通股（A 股）股票 1,325 万股，每股面值人民币 1 元，实际 发行价格为每股人民币 72.89 元，募集资金总额为人民币 96,579.25 万元，扣除 发行费用人民币 9,129.09 万元后实际募集资金净额人民币 87,450.16 万元。扣 除部分发行费用后实际到账金额人民币 90,235.81 万元，其中包括尚未划转的发 行费用人民币 2,785.64 万元。上述资金已于 2020 年 11 月 25 日到账，已经信永 中和会计师事务所（特殊普通合伙 ...

证券代码：605266 证券简称：健之佳 公告编号：2023-055 健之佳医药连锁集团股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，健之佳医药连锁集团股份有限公司（以下简称"公司"） 持股 5%以上股东王雁萍女士持有公司无限售条件流通股份 13,118,069 股，占公 司总股本的 10.1760%，无一致行动人股东；上述股东股份来源为公司首次公开 发行前取得及上市后以资本公积转增股本方式取得，所持股份自公司 2021 年 12 月 1 日起解除限售并上市流通。 减持计划的主要内容 根据相关法律法规及公司首次公开发行上市前王雁萍女士的自愿承诺，其因 自身资金需求，拟自本减持计划公告披露之日起 15 个交易日后的 6 个月内，通 过集合竞价、大宗交易方式减持不超过其直接持有的公司股份 800,000 股无限售 条件流通股，即不超过公司总股数的 0.6206%，减持价格按照市场价格确定。 近日，公司收到王雁萍女 ...

证券代码：605266 证券简称：健之佳 公告编号：2023-027 健之佳医药连锁集团股份有限公司 关于参加 2022 年度云南辖区上市公司投资者网上集体接待日 暨集体业绩说明会的公告 届时公司董事、副总经理、董事会秘书兼财务总监李恒先生将在线就公司 2022 年度及 2023 年 1 季度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 健之佳医药连锁集团股份有限公司董事会 2023 年 5 月 5 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，健之佳医药连锁集团股份有限公司（以 下简称"公司"）将参加由云南证监局、云南省上市公司协会与深圳市全景网络 有限公司联合举办的"2022 年度云南辖区上市公司投资者网上集体接待日暨集 体业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥2,166,874,356.81, representing a 49.41% increase compared to ¥1,450,283,191.81 in the same period last year[5]. - Net profit attributable to shareholders was ¥76,303,944.55, a significant increase of 143.67% from ¥29,365,396.05 in the previous year[5]. - The net profit for Q1 2023 reached 75,474,057.39, an increase of 148.95% compared to 30,317,243.58 in the same period last year[19]. - The basic earnings per share rose to ¥0.77, up 67.39% from ¥0.43 in the same quarter last year[6]. - Operating profit for Q1 2023 was ¥99,383,033.13, up 134.5% from ¥42,443,003.86 in Q1 2022[64]. - The company reported a total comprehensive income of ¥75,474,057.39 for Q1 2023, compared to ¥30,317,243.58 in Q1 2022[65]. - The company reported a net profit attributable to shareholders increased by 143.67% year-on-year[38]. Revenue Growth - Revenue from sales of goods and services was 2,331,854,747.76, representing an 82.39% increase from 1,278,501,199.83 in Q1 2022[19]. - Online channel revenue increased by 62.65% year-on-year, contributing to the overall growth of the multi-channel sales model[40]. - Prescription drug sales revenue grew by 72.88% year-on-year, increasing its share from 31.19% to 36.20%[41]. - The sales revenue of non-prescription drugs increased by 52.22% year-on-year, with its share rising from 37.12% to 37.94%[41]. - The total online revenue for the first quarter of 2023 reached 479.70 million yuan, a 62.65% increase compared to the same period last year[48]. Store Expansion - The number of stores increased by 1,058, resulting in a store growth rate of 33.76% compared to the same period last year[8]. - The total number of stores reached 4,192 in Q1 2023, with a net increase of 137 stores, representing a growth rate of 3.38%[25]. - The company opened 105 new stores and acquired 34 stores during the quarter, while closing 2 stores[26]. - The company is focusing on expanding its store network in key regions such as the Yangtze River Economic Belt and the Guangdong-Hong Kong-Macao Greater Bay Area[24]. - The company is implementing a dual strategy of self-built and acquired stores to penetrate core cities and strengthen its market position in profit centers like Yunnan and Hebei[24]. Cash Flow and Assets - The net cash flow from operating activities was ¥332,485,173.59, a recovery from a negative cash flow of ¥27,843,634.14 in the previous year[6]. - Cash received from operating activities related to other income surged to 48,971,580.78, a dramatic increase of 3,764.55% from 1,267,201.21[19]. - The company's total assets at the end of Q1 2023 were ¥9,460,634,810.71, a slight decrease of 1.91% from ¥9,385,265,346.27 at the end of the previous year[6]. - The company's current assets totaled CNY 3,784,861,062.01, down from CNY 3,939,388,508.01, indicating a decrease of about 3.9%[60]. - The company's cash and cash equivalents decreased to CNY 803,605,541.18 from CNY 932,600,793.46, representing a decline of approximately 13.8%[59]. Cost and Expenses - Operating costs rose to ¥1,460,181,587.44, reflecting a 51.39% increase from ¥964,525,413.43 in the previous year[18]. - Sales expenses increased by 35.98% to ¥532,538,365.18, driven by higher employee compensation, rental fees, and third-party service costs[18]. - Financial expenses rose by 63.65% to ¥32,683,521.27, primarily due to increased interest expenses from short-term and long-term borrowings[18]. - Cash paid for employee compensation increased by 94.13% to 418,381,640.53 from 215,516,673.36, reflecting a rise in workforce and salaries[19]. - Cash paid for various taxes increased by 326.51% to 88,045,895.51 from 20,643,230.49, indicating higher tax obligations due to increased revenue[19]. Strategic Focus - The company is focusing on strategic expansion and enhancing cooperation with prescription drug and OTC brand manufacturers to drive growth[8]. - The company plans to continue expanding its market presence and enhancing service offerings through new store openings and improved supplier relationships[18]. - The company aims to enhance its operational efficiency and brand recognition in county-level and above markets, with 95.36% of stores located in these areas[27]. - The company is committed to a community-oriented service model, positioning itself as a "family doctor, health advisor, and good neighbor" in the community[28]. - The company is focused on building a talent pipeline and management structure to support its expansion strategy[24].

Financial Performance - The company reported a net profit of RMB 136,865,496.39 for 2022, with a proposed cash dividend of RMB 14.6 per 10 shares, totaling RMB 144,711,795.28[5]. - The company's operating revenue for 2022 reached ¥7,514,444,233.35, representing a 43.54% increase compared to ¥5,234,955,418.99 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥363,352,149.44, a 20.90% increase from ¥300,527,439.23 in the previous year[25]. - The net cash flow from operating activities increased by 59.94% to ¥1,190,602,908.19, up from ¥744,403,407.97 in 2021[25]. - The total assets of the company grew by 79.99% to ¥9,385,265,346.27 at the end of 2022, compared to ¥5,214,189,989.48 at the end of 2021[25]. - The net profit after deducting non-recurring gains and losses was ¥361,407,943.96, reflecting a 27.72% increase from the previous year[29]. - The company achieved a net asset return rate of 17.87% in 2022, an increase of 1.20 percentage points from 16.67% in 2021[26]. - The comprehensive gross profit margin in Q4 decreased by 1.56% year-on-year, but revenue growth offset the impact of increased expenses[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 74.01% year-on-year, exceeding the budget performance target for Q4[33]. Store Expansion and Operations - The number of stores increased by 1,011, resulting in a store growth rate of 33.21%[28]. - The company opened 1,011 new stores in 2022, resulting in a total of 4,055 stores by year-end, marking a growth rate of 33.21%[39]. - The company successfully integrated the acquisition of Tangren Medicine, positively impacting operational performance and financial metrics[29]. - The company is focusing on enhancing its omnichannel service capabilities to meet customer demands for convenience and accessibility[32]. - The company expanded its store coverage to 6 provinces and cities after acquiring the Tangren Pharmaceutical project, doubling the number of stores in two years since its IPO[48]. - The company has established a professional health service capability, shifting focus from price competition to long-term health management services[50]. - The company has implemented a multi-channel marketing platform, enhancing online and offline integration, with 448 stores providing 24-hour service to boost performance[54]. - The company is pursuing a dual strategy of "self-built + acquisition" for store expansion, focusing on penetrating county-level markets[94]. Financial Management and Investments - The company plans to allocate 10% of the net profit to statutory reserves, amounting to RMB 13,686,549.64[5]. - The total non-recurring gains and losses for the year included a loss from the disposal of non-current assets amounting to -1,086,228.10 RMB[35]. - The company plans to continue its strategic focus on cost control and efficiency improvements, including reducing rental costs and enhancing promotional effectiveness[32]. - The company reported a significant increase in financial expenses, up 110.90% to ¥101,650,508.01 from ¥48,199,535.07[77]. - The net cash flow from investing activities was negative at -¥2,498,650,998.36, primarily due to the acquisition of assets and companies[78]. - The company has invested in a standardized chain management system and refined operational management to improve store efficiency and customer service[54]. - The company has invested over ¥9.5 billion in logistics infrastructure, expanding warehouse space to over 200,000 square meters to support business growth[73]. Market Strategy and Competitive Positioning - The company aims to enhance its service offerings through a comprehensive multi-channel service platform, integrating community pharmacies, convenience stores, and health service centers[46]. - The company is committed to a nationwide expansion strategy, leveraging its established brand influence and operational capabilities in the Southwest region[46]. - The company is focusing on chronic disease management and has established independent chronic disease files for each member, utilizing big data for better service delivery[141]. - The retail pharmacy market in China was valued at 544.9 billion yuan in 2021, with a year-on-year growth of 7.4%[42]. - The company is adapting to policy changes in the healthcare sector that have impacted its operations, particularly in regions where it operates[94]. - The company is facing industry policy risks due to ongoing healthcare reforms, which may lead to operational challenges if internal controls are not adjusted accordingly[148]. - The company is committed to a strategic focus on "health, professionalism, and convenience," aiming for sustainable development and improved governance[134]. Governance and Compliance - The company held 4 shareholder meetings during the reporting period, ensuring all shareholders, especially minority shareholders, were treated equally and their rights protected[157]. - The board of directors consists of 7 members, including 3 independent directors, and held 8 meetings during the reporting period to ensure effective governance[158]. - The supervisory board, comprising 3 members, conducted 7 meetings to oversee the company's operations and financial status, safeguarding shareholder interests[158]. - The company strictly adhered to legal and regulatory requirements for information disclosure, ensuring transparency and fairness in its operations[158]. - The company emphasized the importance of compliance with the regulations set by the China Securities Regulatory Commission regarding major asset restructuring[162]. - The company has a structured internal control system that governs the remuneration of its internal directors and supervisors[173]. Employee Engagement and Development - The company has implemented a stock incentive plan to enhance employee engagement and retention[59]. - The company will implement a three-year employee training and development plan focused on supporting rapid business expansion and enhancing professional service capabilities[189]. - The company has established a performance evaluation system that closely ties employee compensation to individual performance, fostering a high-performance work environment[188]. - The company plans to increase the proportion of professional staff through targeted recruitment of licensed pharmacists and experienced management personnel[190]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 7.537 million yuan[173]. Acquisitions and Strategic Growth - The company completed two equity acquisitions during the reporting period, totaling an investment of RMB 1,730.28 million, acquiring 718 stores[114]. - The company signed an agreement to acquire 80% of Hebei Tangren Pharmaceutical for RMB 1,658.80 million, with the first phase of the transaction completed on August 31, 2022[115]. - The acquisition of Tangren Pharmaceutical is expected to significantly enhance the company's market penetration and bargaining power with suppliers[120]. - The integration of Tangren Pharmaceutical was completed smoothly, with a net profit contribution of RMB 72,175,447.88 from September to December 2022, exceeding the performance commitment by 22.88%[124]. - The company plans to continue the management integration and business enhancement of Tangren Pharmaceutical through 2023, aiming for a comprehensive budget control[122]. Risks and Challenges - The company faces risks related to cross-regional acquisitions, including challenges in managing new market characteristics and potential integration issues[152]. - There is a significant risk of goodwill impairment following acquisitions, which could adversely affect future operating performance if market conditions change[153]. - The company anticipates a long-term decline in gross profit margins due to policies like "two-invoice system" and "volume-based procurement" affecting pricing structures[151]. - The overall market environment remains challenging, with increased competition in the pharmaceutical retail sector impacting profit margins[86].

关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 8 日(星期一) 上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 证券代码：605266 证券简称：健之佳 公告编号：2023-012 健之佳医药连锁集团股份有限公司 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 27 日(星期四) 至 5 月 5 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@jzj.cn 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 健之佳医药连锁集团股份有限公司（以下简称"公司"）将于 2023 年 4 月 27 日发布公司 2022 年度报告及 2023 年一季度报告，为便于广大投资者更全面深入 地了解公司 2022 年度 ...

Financial Performance - The company's operating revenue for Q3 2022 reached ¥1,702,769,381.83, representing a year-on-year increase of 32.29%[6]. - The net profit attributable to shareholders for Q3 2022 was ¥104,761,137.59, reflecting a 41.94% increase compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥102,609,749.41, up 45.81% year-on-year[6]. - The company's operating revenue for the first nine months of 2022 reached ¥47,089,613,386.37, representing a year-on-year growth of 28.43%[69]. - The company reported a total revenue of approximately RMB 1.11 billion for the first nine months of 2022, with a net profit of approximately RMB 45.21 million[41]. - The net profit for Tangren Pharmaceutical in September 2022 was approximately RMB 8.37 million, contributing positively to the company's consolidated financial results[41]. - The company reported a total liability of approximately ¥6.43 billion, which is an increase from ¥3.32 billion, representing a growth of about 93.5%[110]. Asset and Equity Growth - The total assets at the end of the reporting period were ¥8,809,136,337.16, an increase of 68.95% compared to the end of the previous year[9]. - The equity attributable to shareholders increased by 25.50% year-on-year, amounting to ¥2,396,746,682.66[9]. - The company's total assets increased to RMB 8,809,136,337.16 in 2022 from RMB 5,214,189,989.48 in 2021, reflecting a growth of 68.5%[112]. - The company's retained earnings rose to RMB 855,065,177.06 in 2022, compared to RMB 782,541,844.74 in 2021, indicating an increase of 9.3%[112]. - The total equity attributable to shareholders of the parent company increased to RMB 2,396,746,682.66 in 2022 from RMB 1,909,745,632.14 in 2021, marking a growth of 25.5%[112]. Cash Flow and Financing - The company reported a net cash flow from operating activities of ¥821,505,897.27 for the year-to-date, reflecting a 49.87% increase[9]. - The company generated cash flow from operating activities of RMB 4,652,948,626.85 in the first three quarters of 2022, up from RMB 3,624,962,318.34 in 2021, representing a growth of 28.3%[118]. - Cash inflow from financing activities reached CNY 2,068,942,730.48, significantly higher than CNY 25,752,493.00[123]. - Net cash flow from financing activities was CNY 1,385,348,520.51, a recovery from -CNY 549,190,133.51[123]. - The ending cash and cash equivalents balance was CNY 450,978,692.23, down from CNY 902,972,943.04[123]. Acquisition and Integration - The company completed the acquisition of 100% equity of Hebei Tangren Pharmaceutical Co., Ltd. (Tangren Pharmaceutical) through a cash payment, with the total transaction price amounting to RMB 2,073.50 million, including expected cash dividends of RMB 30.97 million[19]. - The fair value of identifiable net assets acquired from Tangren Pharmaceutical at the acquisition date was assessed at RMB 307.94 million, resulting in goodwill of RMB 1,769.21 million due to the excess of acquisition cost over the fair value of net assets[22]. - The company has initiated integration efforts for Tangren Pharmaceutical to ensure smooth operational consolidation following the acquisition[19]. - Tangren Pharmaceutical was fully consolidated into the company's financial statements starting September 1, 2022, with total assets of approximately RMB 949.98 million and total liabilities of approximately RMB 601.11 million as of September 30, 2022[41]. - The acquisition is structured as a "package transaction," with the accounting treatment reflecting the interdependence of the two phases of the transaction[19]. Operational Challenges and Strategies - The company faced challenges due to external uncertainties and pandemic impacts but managed to achieve steady growth through strategic adjustments and risk control measures[10]. - The company plans to continue expanding its physical store network and enhance online and offline sales channels to drive future growth[11]. - The company is actively expanding its store network, focusing on core cities and adopting a dual strategy of "self-built + acquisition" to maintain rapid and stable growth, particularly in the Yunnan region[49]. - The company aims to expand its market presence from 4 provinces to 6, marking a strategic step towards national coverage[53]. - The company is focusing on enhancing management and talent development in provincial branches to strengthen operational efficiency[53]. Sales and Revenue Composition - Prescription drug sales accounted for 32.33% of total revenue, with a year-on-year increase of 1.22%[70]. - The retail sector's revenue structure showed a notable increase in the share of non-prescription drugs, which rose to 38.27%[70]. - Over-the-counter drug sales revenue grew by 40.10% year-on-year, with the structural proportion increasing from 35.07% to 38.27%[81]. - The sales revenue of private label products accounted for 12.60% of the main business income, up from 12.47% in the previous year[83]. - Online business revenue reached 95,506.49 million yuan, a year-on-year increase of 70.65%, representing 20.28% of total revenue[89]. Inventory and Receivables - Cash and cash equivalents decreased by 29.36% primarily due to the use of self-owned funds for the acquisition of Tangren Pharmaceutical's equity[32]. - Accounts receivable increased by 106.06% due to the growth in business scale, including the integration of Tangren Pharmaceutical, and an increase in the number of medical insurance stores[32]. - Inventory rose by 74.89% as a result of increased store numbers, rapid growth in online channels, and precautionary stocking to mitigate potential supply chain disruptions[32]. - The company reported a significant increase in goodwill by 440.31% as a result of the completion of the Tangren Pharmaceutical acquisition[32]. Cost Management - The company's sales expenses increased by 36.78% year-on-year, mainly due to the increase in employee compensation as the number of stores grew[37]. - The company is focusing on cost control measures, including reducing rental costs and improving promotional effectiveness to boost gross margins[100]. - The company is leveraging rapid growth in revenue and procurement scale to secure more rebates and marketing funds from pharmaceutical manufacturers[100].